VMD Stock Analysis: Viemed Healthcare | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 463m USD | 12M Return: 76.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.67M
EPS Trend: 92.8%
Qual. Beats: -1
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 8.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viemed Healthcare is a Lafayette, Louisiana-based provider of home medical equipment (HME) and post-acute respiratory care services across the United States. Founded in 2006, the company focuses on managing chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), offering non-invasive ventilation, percussion vests, oxygen therapy, and related supplies. Beyond its core respiratory business, Viemed also provides sleep apnea diagnostics and equipment, neuromuscular and oxygen therapy services, in-home sleep testing, breast pump and lactation supplies, and healthcare staffing and recruitment services.
The U.S. home medical equipment sector is shaped by reimbursement frameworks from Medicare and private insurers, which dictate pricing and coverage for respiratory and durable medical equipment. Post-acute and home-based care has gained share within the broader healthcare system as payers and providers seek lower-cost alternatives to facility-based treatment, particularly for chronic respiratory and sleep-related conditions that require long-term equipment use.
- COPD patient growth drives ventilator rental revenue
- Medicare reimbursement rate changes impact HME margins
- Sales force expansion accelerates new patient starts
| Net Income: 14.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 16.77 > 1.0 |
| NWC/Revenue: 3.18% < 20% (prev 5.86%; Δ -2.68% < -1%) |
| CFO/TA 0.29 > 3% & CFO 57.1m > Net Income 14.9m |
| Net Debt (5.91m) to EBITDA (53.0m): 0.11 < 3 |
| Current Ratio: 1.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.5m) vs 12m ago -2.73% < -2% |
| Gross Margin: 57.32% > 18% (prev 58.71%; Δ -1.39% > 0.5%) |
| Asset Turnover: 152.7% > 50% (prev 130.7%; Δ 21.93% > 0%) |
| Interest Coverage Ratio: 17.89 > 6 (EBIT TTM 23.4m / Interest Expense TTM 1.31m) |
| A: 0.05 (Total Current Assets 49.8m - Total Current Liabilities 40.7m) / Total Assets 197.4m |
| B: 0.53 (Retained Earnings 105.5m / Total Assets 197.4m) |
| C: 0.12 (EBIT TTM 23.4m / Avg Total Assets 187.7m) |
| D: 2.79 (Book Value of Equity 143.9m / Total Liabilities 51.6m) |
| Altman-Z'' = 5.81 = AAA |
| DSRI: 0.95 (Receivables 31.2m/26.8m, Revenue 286.6m/232.8m) |
| GMI: 1.02 (GM 58.71% / 57.32%) |
| AQI: 1.37 (AQ_t 0.35 / AQ_t-1 0.25) |
| SGI: 1.23 (Revenue 286.6m / 232.8m) |
| TATA: -0.21 (NI 14.9m - CFO 57.1m) / TA 197.4m) |
| Beneish M = -2.69 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 12.31 with a total of 235,317 shares traded. Over the past week, the price has changed by +2.41%, over one month by +21.52%, over three months by +29.44% and over the past year by +76.36%.
Current recommended Stop Loss: 11.80 (which is 4.1% or 1.4 ATR below the current price).
Viemed Healthcare has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy VMD.
- StrongBuy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11 | -10.6% |
P/E Trailing = 32.6216
P/E Forward = 27.6243
P/S = 1.6147
P/B = 3.2085
Revenue TTM = 286.6m USD
EBIT TTM = 23.4m USD
EBITDA TTM = 53.0m USD
Long Term Debt = 8.33m USD (from longTermDebt, last quarter)
Short Term Debt = 2.07m USD (from shortTermDebt, last quarter)
Debt = 15.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.23m
Net Debt = 5.91m USD (calculated: Debt 15.7m - CCE 9.76m)
Enterprise Value = 468.6m USD (462.7m + Debt 15.7m - CCE 9.76m)
Interest Coverage Ratio = 17.89 (Ebit TTM 23.4m / Interest Expense TTM 1.31m)
EV/FCF = 18.08x (Enterprise Value 468.6m / FCF TTM 25.9m)
FCF Yield = 5.53% (FCF TTM 25.9m / Enterprise Value 468.6m)
FCF Margin = 9.04% (FCF TTM 25.9m / Revenue TTM 286.6m)
Net Margin = 5.20% (Net Income TTM 14.9m / Revenue TTM 286.6m)
Gross Margin = 57.32% ((Revenue TTM 286.6m - Cost of Revenue TTM 122.3m) / Revenue TTM)
Gross Margin QoQ = 56.27% (prev 57.89%)
Tobins Q-Ratio = 2.37 (Enterprise Value 468.6m / Total Assets 197.4m)
Interest Expense / Debt = 8.35% (Interest Expense 1.31m / Debt 15.7m)
Taxrate = 30.40% (6.72m / 22.1m)
NOPAT = 16.3m (EBIT 23.4m * (1 - 30.40%))
Current Ratio = 1.22 (Total Current Assets 49.8m / Total Current Liabilities 40.7m)
Debt / Equity = 0.11 (Debt 15.7m / totalStockholderEquity, last quarter 143.9m)
Debt / EBITDA = 0.11 (Net Debt 5.91m / EBITDA 53.0m)
Debt / FCF = 0.23 (Net Debt 5.91m / FCF TTM 25.9m)
Total Stockholder Equity = 139.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.93% (Net Income 14.9m / Total Assets 197.4m)
RoE = 10.66% (Net Income TTM 14.9m / Total Stockholder Equity 139.7m)
RoCE = 15.81% (EBIT 23.4m / Capital Employed (Equity 139.7m + L.T.Debt 8.33m))
RoIC = 10.94% (NOPAT 16.3m / Invested Capital 149.0m)
WACC = 7.17% (E(462.7m)/V(478.4m) * Re(7.22%) + D(15.7m)/V(478.4m) * Rd(8.35%) * (1-Tc(0.30)))
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.67 | Cagr: 0.12%
[DCF] Terminal Value 75.44% ; FCFF base≈25.9m ; Y1≈26.0m ; Y5≈27.6m
[DCF] Fair Price = 11.03 (EV 428.8m - Net Debt 5.91m = Equity 422.9m / Shares 38.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 92.82 | EPS CAGR: 22.46% | SUE: -1.52 | # QB: -1
Revenue Correlation: 99.42 | Revenue CAGR: 22.79% | SUE: 0.91 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-16.67% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.13 | Chg30d=+4.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=-5.21% | Revisions=-40% | GrowthEPS=+23.0% | GrowthRev=+17.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg30d=-1.61% | Revisions=+0% | GrowthEPS=+34.1% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: -29% (up=1, down=3)